Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh Ph Patel sold 65,761 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $149.11, for a total transaction of $9,805,622.71. Following the completion of the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at $78,055,804.58. This represents a 11.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Price Performance

• Johnson & Johnson's M&A Strategy Is the Real Story for Investors

NASDAQ PTGX opened at $152.01 on Thursday. Protagonist Therapeutics, Inc. has a 12 month low of $54.18 and a 12 month high of $152.70. The company has a market capitalization of $9.84 billion, a P/E ratio of 147.58 and a beta of 1.78. The company's 50 day simple moving average is $127.64 and its 200 day simple moving average is $106.78.

---

---

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, topping analysts' consensus estimates of $2.27 by $0.02. The firm had revenue of $213.47 million during the quarter, compared to analysts' expectations of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm's revenue was up 3746.8% compared to the same quarter last year. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 4.02 earnings per share for the current year.

Hedge Funds Weigh In On Protagonist Therapeutics

• Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PTGX. Farther Finance Advisors LLC grew its position in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at $27,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of Protagonist Therapeutics in the second quarter valued at $30,000. Allworth Financial LP acquired a new stake in shares of Protagonist Therapeutics in the second quarter worth $31,000. Finally, Quantbot Technologies LP purchased a new position in shares of Protagonist Therapeutics during the second quarter valued at $42,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: An analyst article maintained a “Strong Buy” view, citing FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, attractive partnership economics and additional pipeline opportunities. Investors are also watching the FDA’s expected August 2026 Priority Review decision for rusfertide, which could lead to significant milestones and royalty payments from Takeda. The company plans to begin a Phase 2b study of oral IL-17 antagonist PN-881 in the first quarter of 2027. Protagonist Therapeutics: Strong Buy—ICOTYDE FDA Approval and PN-881 Advancement
• Positive Sentiment: A psoriasis-focused stock roundup included PTGX among companies offering exposure to approved therapies, late-stage candidates and earlier-stage psoriasis programs. This reinforces investor interest in Protagonist’s inflammatory-disease pipeline, although the article does not provide a new company-specific catalyst. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear anomalous, they provide little meaningful indication of near-term short-covering or bearish pressure.
• Negative Sentiment: CEO Dinesh V. Patel sold a combined 100,000 shares for approximately $14.9 million in transactions dated August 10 and 11. The sales reduced his reported ownership, which can pressure sentiment; however, both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, making them less indicative of a fresh change in management’s outlook. SEC insider transaction filing

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PTGX. Johnson Rice set a $165.00 price objective on Protagonist Therapeutics in a research note on Friday, July 17th. UBS Group raised Protagonist Therapeutics to a "buy" rating in a research report on Monday. The Goldman Sachs Group raised Protagonist Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $110.00 to $186.00 in a report on Monday. Wall Street Zen lowered Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $137.86.

Check Out Our Latest Research Report on Protagonist Therapeutics

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

Featured Articles

• Five stocks we like better than Protagonist Therapeutics
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].